‎Basma Adeem to debut on Nomu on Feb. 3

‎Basma Adeem to debut on Nomu on Feb. 3 ‎Basma Adeem to debut on Nomu on Feb. 3

​‎

Logo ofBasma Adeem Medical Co.

The Saudi Exchange (Tadawul) announced that shares of Basma Adeem Medical Co. will start trading on the Nomu-Parallel Market on Feb. 3, with the symbol 9626 and ISIN Code SA168G24MD19.

Advertisement

The stock will trade with daily and static price fluctuation limits of +/-30% and +/-10%, respectively.

For More IPOs

The Securities Depository Center Co. (Edaa) said the company’s subscribed securities were deposited today, Jan. 30, into the accounts of eligible shareholders.

According to Argaamdata, Basma Adeem earlier floated four million shares, or 25% of the company’s pre-IPO capital, currently valued at SAR 16 million, divided into 16 million shares with a nominal value of SAR 1 each. These shares also make up 20% of the post-IPO capital.

The final offering price was set at SAR 4.40 per share, with a coverage rate of 198.27%.

 

Logo ofBasma Adeem Medical Co.

The Saudi Exchange (Tadawul) announced that shares of Basma Adeem Medical Co. will start trading on the Nomu-Parallel Market on Feb. 3, with the symbol 9626 and ISIN Code SA168G24MD19.

The stock will trade with daily and static price fluctuation limits of +/-30% and +/-10%, respectively.

For More IPOs

The Securities Depository Center Co. (Edaa) said the company’s subscribed securities were deposited today, Jan. 30, into the accounts of eligible shareholders.

According to Argaamdata, Basma Adeem earlier floated four million shares, or 25% of the company’s pre-IPO capital, currently valued at SAR 16 million, divided into 16 million shares with a nominal value of SAR 1 each. These shares also make up 20% of the post-IPO capital.

The final offering price was set at SAR 4.40 per share, with a coverage rate of 198.27%.

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with our Weekly Newsletter

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement